1959.8000 7.40 (0.38%)
NSE Aug 27, 2026 15:31 PM
Volume: 122.2K
 

1959.80
0.38%
Emkay
Ipca’s 4QFY26 EBITDA was ahead of our expectations (broadly in line with the consensus’). The beat was driven by higher overall sales, a marginally higher gross margin, as well as lower staff costs.
Emkay increased Buy price target of Ipca Laboratories Ltd. to 1950.0 on 17 Aug, 2026.
More from Ipca Laboratories Ltd.
Recommended